Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 23, 2017
Pharmacy Choice - News - Generic Drugs - April 23, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/24/17 - Amring Pharmaceuticals Acquired Six ANDAs
By a News Reporter-Staff News Editor at Drug Week Amring Pharmaceuticals Inc., a generic pharmaceutical company, announced that it acquired six ANDAs from Luitpold Pharmaceuticals, Inc. and AlphaForce, L.L.P., a joint venture between Luitpold Pharmaceuticals, Inc. and Alphagen Laboratories Inc. Acquired ANDAs include niche otic and ophthalmic...
3/24/17 - Biogaran takes over Swipha's activities in Nigeria to produce quality generic medicines for the local market
LAGOS, Nigeria Biogaran, a French pharmaceutical company specialized in generic and biosimilar medicines, and a subsidiary of Servier, today announced the takeover of all the activities of Swipha, a Nigerian company that manufactures and distributes pharmaceutical products known for their quality. This is an important step forward in the...
3/24/17 - Biogaran takes over Swipha's activities in Nigeria to produce quality generic medicines for the local market A strong commitment to make quality, accessible, affordable medicines available to patients
Biogaran, a French pharmaceutical company specialized in generic and biosimilar medicines, and a subsidiary of Servier, today announced the takeover of all the activities of Swipha, a Nigerian company that manufactures and distributes pharmaceutical products known for their quality. This is an important step forward in the internationalization of t
3/24/17 - Biosimilar of costly inflammatory bowel disease therapy found safe and effective
By a News Reporter-Staff News Editor at Drug Week Treatment of Crohn's disease and ulcerative colitis has been greatly improved by the introduction of biologic therapies such as infliximab, but at considerable cost. CT-P13 has been recently approved in the United States, the European Union, Australia, Canada, Japan, and many other countries.
3/24/17 - FDA Approves First-ever Merkel Cell Carcinoma Drug, HTGM Riding High, FLXN Soars
THOUSAND OAKS- The European Commission has approved Amgen's AMGEVITA as a biosimilar to Humira for the treatment of certain inflammatory diseases. AMGEVITA is Amgen's first biosimilar to be approved by the European Commission. AMGEVITA was approved in the United States by the FDA last September.
3/24/17 - French Firm Takes Over Nigerian Drug Manufacturing Company, Swipha
Biogaran, a French pharmaceutical company specialised in generic and biosimilar medicines, and a subsidiary of Servier, on Friday announced the takeover of all the activities of Swipha, a Nigerian company that manufactures and distributes pharmaceutical products known for their quality. This is an important step forward in the internationalisation
3/24/17 - Global Biologics and Biosimilars Market-Pfizer, Changchun High Tech, Dong Bao, Eli Lilly, GanleeRoche
Pune, Mahrashtra 03/23/2017 The motive of this strategic research report entitled "Global Biologics and Biosimilars Market 2017-2022" is to provide company officials, industry investors, and Biologics and Biosimilars industry members with consequential insights to enable them make reliable strategic decisions regarding the opportunities in th
3/24/17 - Medicure Announces FDA Approval for Apicore's Generic Tetrabenazine
Release date- 23032017- WINNIPEG- Medicure Inc., a leading Canadian specialty pharmaceutical company, is pleased to announce that its majority-owned subsidiary, Apicore Inc., has received final approval from the U.S. Food and Drug Administration for the Company's abbreviated new drug application for tetrabenazine tablets in the 12.5 mg and 25 mg st
3/24/17 - Mylan Launches Generic Pristiq Tablets
By a News Reporter-Staff News Editor at Drug Week- Mylan N.V., announced the U.S. launch of Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, a generic version of Pfizer's Pristiq Tablets. Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, had U.S. sales of approximately $853 million for the 12 months ending January 31, 2017,
3/24/17 - NuGlobal Healthcare, LLC: Founded to innovate and revolutionize generic pharmaceutical industry using proprietary niche technologies and decades.
NuGlobal Healthcare, LLC is founded to innovate and revolutionize generic pharmaceutical industry using proprietary niche technologies and decades of value driven pharmaceutical experience to deliver quality drug products focusing patients unmet needs and affordability by de-risking and maximizing investor capital. NuGlobal Healthcare jointly...
3/24/17 - PCI Synthesis Wins Big at 2017 Life Science Leader Magazine CMO Leadership Awards [Sudan Tribune]
PCI Synthesis, Inc., a pharmaceutical manufacturer of new chemical entities, generic active pharmaceutical ingredients, and other specialty chemical products, today announced that it was recognized as the "Top Overall Performer" in every category the awards are given: Quality, Reliability, Capabilities, Expertise, Compatibility, and Development.
3/24/17 - Switzerland wants stricter intellectual property rules in India that could harm generic drug makers [Tehran Times (Iran)]
Developed countries continue to put pressure on India to move to stricter intellectual property regimes that would favour multinational pharmaceutical countries over generic drug manufacturers. A new leaked document shows that the Swiss government is pushing for more patent protections and data exclusivity in negotiations for the Trade and Economic
3/24/17 - Teligent, Inc. Announces FDA Approval Of Clobetasol Propionate Gel, 0.05%
By a News Reporter-Staff News Editor at Drug Week Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, announced it has received approval of the Company's abbreviated new drug application from the U.S. Food and Drug Administration of Clobetasol Propionate Gel, 0.05%. This is Teligent's second approval for 2017, and its th
3/24/17 - Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Denies Reports Of Layoffs As Company Lowers Revenue Guidance
Though Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has indicated that it plans to freeze recruitment and end all unprofitable activities, the Israeli firm has denied reports that appeared in the media that indicated the pharmaceutical company intended to lay off close to 6,000 employees. The reports had appeared in two Israeli news website
3/24/17 - Teva said to plan cuts of as many as 6,000 jobs globally [T-break Tech (Middle East)]
Israels Teva Pharmaceutical Industries Ltd., the worlds largest maker of generic drugs, has reportedly started a process of worker layoffs at its plants and HQ in Israel and is planning a second wave of even deeper cuts after the Passover holidays in April. Teva has already fired some 100 workers in Israel, the website reported. As of end 2016, the
3/24/17 - US FDA criticizes Indian drug firm USV for problems at multiple sites [Sudan Tribune]
You should immediately and comprehensively assess your companys global manufacturing operations to ensure that systems and processes, and ultimately, the products manufactured, conform to FDA requirements. The letter to USV is similar to a warning sent to fellow Indian drug manufacturer Wockhardt this month in which the US agency detailed problems.
3/24/17 - VANC Pharmaceuticals Provides Marketing Update
VANC Pharmaceuticals Inc., a pharmaceutical company focused on the Canadian generic drug and over-the-counter markets provides marketing update as part of its ongoing program to bring value added products to the Canadian pharmacy industry. "I am pleased to announce that VANC's premium natural iron supplement Hema-Fer? has been accepted by two ph
3/23/17 - 2016 Annual Report DTR 6.3.5 Disclosure
2016 Annual Report- DTR 6.3. 5 Disclosure March 23, 2017- Shire plc announces that the following documents have today been posted or otherwise will be made available to shareholders:* 2016 Annual Report* Notice of the 2017 Annual General Meeting* Form of Proxy In accordance with Listing Rule 9.6. 1 R, a copy of each of these documents will be uploa
3/23/17 - Amgen targets Roche in Europe with Herceptin biosimilar submission [Syrian Arab News Agency]
According to Amgens presentation from March 8, ABP 980 is yet to have been submitted to the US Food and Drug Administration for review, though this is planned for the near future. Mylan and Biocon are believed to be the first firms to have a Herceptin biosimilar accepted for review in the US, with the FDA setting a Biosimilar User Fee Act target ac
3/23/17 - Argentum Persists in Challenging the "Evergreening" Patent on UCB's VIMPAT
In addition to reaching settlements granting Argentum Pharmaceuticals LLC rights to market lower-cost generics of other patented drugs, Argentum continues to challenge the sole remaining patent covering UCB's VIMPAT drug in the U.S. Patent& Trademark Office. After obtaining successful institution of its challenge at the PTO where other challen
3/23/17 - Bio Farma to produce breast cancer biosimilar at lower price [Philippines News Agency]
Vaccine producer Bio Farma said it would launch and sell biosimilar specially for breast cancer at a cheaper price. Erman said Bio Farma plans to sell its biosimilar more than 50 percent cheaper than biosimilar for breast cancers produced by the Swiss based La Roche priced at Rp25 million per dosage. Breast cancer biosimilar of La Roche is patented
3/23/17 - Generic drug company monopolies and regulatory barriers
With Republican efforts to repeal and replace Obamacare dominating the headlines, you might have missed the hearing yesterday in the House Subcommittee on Health Care, Benefits, and Administrative Rules examining "the impact of voluntary restricted distribution systems in the pharmaceutical supply chain." The hearing explored how some generic drug.
3/23/17 - Lupin receives FDA approval for generic TOBI inhalation solution [India Infoline News Service]
Pharma Major Lupin Limited announced today that it has received final approval for its Tobramycin Inhalation Solution USP, 300 mg/5 ml from the United States Food and Drug Administration to market a generic version of Novartis Pharmaceuticals Corporation's TOBI 300 mg/5 ml. Pharma Major Lupin Limited announced today that it has received final appro
3/23/17 - Medicure Announces FDA Approval for Apicore's Generic Tetrabenazine
-Medicure Inc., a leading Canadian specialty pharmaceutical company, is pleased to announce that its majority-owned subsidiary, Apicore Inc., has received final approval from the U.S. Food and Drug Administration for the Company's abbreviated new drug application for tetrabenazine tablets in the 12.5 mg and 25 mg strengths. Medicure currently owns.
3/23/17 - NuGlobal Healthcare, LLC: Founded to innovate and revolutionize generic pharmaceutical industry using proprietary niche technologies and decades.
NuGlobal Healthcare, LLC is founded to innovate and revolutionize generic pharmaceutical industry using proprietary niche technologies and decades of value driven pharmaceutical experience to deliver quality drug products focusing patients unmet needs and affordability by de-risking and maximizing investor capital. N...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415